Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | DCAF15 | Q66K64 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494466 | 1.00 | P2RX3 (0.59) | P2RX3CYP2C9DCAF15F2HRH4 | |
| SCHEMBL20023788 | 0.93 | P2RX3 (0.60) | P2RX3CYP2C9DCAF15F2HRH4 | |
| SCHEMBL31494477 | 0.93 | P2RX3 (0.60) | P2RX3CYP2C9DCAF15F2HRH4 | |
| SCHEMBL4228916 | 0.74 | P2RX3 (1.00) | P2RX3CYP2C9 | |
| SCHEMBL4228721 | 0.72 | P2RX3 (0.97) | P2RX3CYP2C9 | |
| SCHEMBL20023791 | 0.70 | P2RX3 (0.59) | P2RX3CYP2C9 | |
| SCHEMBL20023805 | 0.70 | P2RX3 (0.49) | P2RX3CYP2C9HSD17B10 | |
| SCHEMBL20023789 | 0.70 | P2RX3 (0.59) | P2RX3CYP2C9 | |
| SCHEMBL31494493 | 0.70 | P2RX3 (0.59) | P2RX3CYP2C9 | |
| SCHEMBL31494473 | 0.70 | P2RX3 (0.49) | P2RX3CYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2019-03-28 | — | — | US | disclosed |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018064135-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885CYP2C9 1672/4885DCAF15 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.